Thymosin Beta-4

Mechanism

The full-length version of the protein that TB-500 comes from. It's a 43-amino acid protein found in nearly every cell of your body. It promotes wound healing, reduces inflammation, and helps generate new blood vessels. TB-500 is just the active fragment — Thymosin Beta-4 is the complete molecule.

Effects

**Musculoskeletal System (Tier 1 — Human Clinical + Extensive Animal):** Thymosin Beta-4 is a 43-amino-acid peptide that is the primary G-actin sequestering molecule in mammalian cells. It promotes tissue repair by facilitating cell migration, reducing inflammation, and promoting angiogenesis. As the full-length molecule (vs TB-500 fragment), it retains all biological activities including actin regulation, anti-inflammatory signaling, and stem cell recruitment. **Cardiovascular System (Tier 2 — Animal):** Comprehensive cardioprotective effects demonstrated in MI models: reduces infarct size, activates resident cardiac progenitor cells (c-kit+ cells), promotes epicardial cell-mediated neovascularization, and improves left ventricular function. The full-length molecule has been studied more extensively than TB-500 in cardiac models. **Ocular System (Tier 1 — Human Clinical):** Phase III clinical trials for neurotrophic keratopathy and dry eye disease. RGN-259 (thymosin beta-4 ophthalmic solution) demonstrated statistically significant improvements in corneal fluorescein staining and symptom scores. **Immune System (Tier 2 — Animal + In Vitro):** Modulates T-cell maturation and differentiation. Anti-inflammatory effects through NF-kB suppression, reduced neutrophil chemotaxis to injury sites, and promotion of regulatory T-cell populations. Reduces fibrosis across organ systems. **Nervous System (Tier 2 — Animal):** Promotes neural progenitor cell proliferation, oligodendrocyte maturation, and axonal remodeling in stroke and TBI models. BBB-permeable. Functional neurological improvement observed in rodent stroke models.

Practitioner Guide

**CLINICAL CONTEXT:** • Thymosin Beta-4 (full-length, 43 amino acids) and TB-500 (synthetic fragment) are often conflated in clinical practice. Most commercially available "TB-500" is actually a synthetic version of the full TB-4 sequence or its active fragment. • The full-length TB-4 molecule is used in the RGN-259 ophthalmic formulation and some clinical research settings. In peptide therapy practice, "TB-500" is the standard product name. • Dosing and protocols for TB-500 apply to TB-4 as well. See the TB-500 entry for comprehensive practitioner protocols. **UNIQUE CONSIDERATIONS FOR FULL-LENGTH TB-4:** • The full-length molecule may have additional bioactivity compared to fragments, particularly regarding intracellular actin regulation and nuclear signaling, but this has not been clinically differentiated in practice. • Some compounding pharmacies specifically offer "Thymosin Beta-4" (full-length) as a premium product. Practitioners report no clinically meaningful difference in outcomes vs standard TB-500 for musculoskeletal applications. **OPHTHALMIC USE:** • For corneal healing and dry eye: Thymosin Beta-4 0.1% ophthalmic solution (RGN-259 formulation), 1 drop in each affected eye twice daily. This is the formulation used in Phase III clinical trials. • Not yet commercially available — clinical trial formulation only. Some compounding pharmacies may prepare thymosin beta-4 ophthalmic preparations under physician orders.

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  Thymosin beta-4 promotes angiogenesis, cell migration, and tissue remodeling. These mechanisms may directly support tumor vascularization, facilitate tumor cell migration and metastasis, and promote tumor growth. Elevated thymosin beta-4 has been found in several tumor types.
  Action: Do not use in patients with any active cancer diagnosis. Patients with cancer history within the past 5 years should consult their oncologist.
• hard stop — Pregnancy
  No human safety data during pregnancy. Angiogenic and cell migration-promoting properties pose theoretical risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Research peptide. Not for pediatric use.
  Action: Do not provide to individuals under 18.

Evidence

• Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial

  Sosne G, Dunn SP, Kim C (2015) — Ophthalmic Research — PMID: 25791377

  Thymosin beta-4 (RGN-259) ophthalmic solution significantly improved signs and symptoms of dry eye disease vs placebo in a Phase 2 RCT. Improvements were seen in corneal fluorescein staining (primary endpoint), ocular discomfort, and tear film breakup time. The peptide promotes corneal epithelial healing and has anti-inflammatory properties.

  moderate

• Thymosin beta4 increases hair growth by activation of hair follicle stem cells

  Philp D, Nguyen M, Scheremeta B, St-Surin S, Villa AM, Bhatt A, Atber YN, Bhatt SP, Kleinman HK (2004) — FASEB Journal — PMID: 15319373

  Thymosin beta-4 promoted hair growth in rats and mice through activation of hair follicle stem cells. The peptide stimulated migration and differentiation of follicular progenitor cells. Also demonstrated wound healing acceleration with increased angiogenesis, collagen deposition, and keratinocyte migration. Effects mediated through actin-binding and anti-inflammatory mechanisms.

  moderate

• Thymosin beta4 accelerates wound healing

  Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK (1999) — Journal of Investigative Dermatology — PMID: 10469339

  Thymosin beta-4 significantly accelerated wound closure in aged mice and rats. Topical and systemic administration enhanced dermal wound healing through promotion of cell migration, angiogenesis, and collagen deposition. Identified thymosin beta-4 as a major actin-sequestering peptide involved in wound repair signaling.

  moderate

Stacks featuring this peptide

Research Summary

**Tier 1 (Human Clinical Evidence):** • Dry eye / neurotrophic keratopathy: Phase II/III trials (RegeneRx Biopharmaceuticals) demonstrate significant corneal healing and symptom relief with topical TB-4 ophthalmic solution. Multiple endpoints met including corneal staining improvement. • Pressure ulcers: Phase II trial showed improved healing of pressure ulcers in elderly patients with topical TB-4 gel. Statistically significant acceleration of wound closure. • Safety: Excellent safety profile across all human studies. No serious adverse events attributed to TB-4 in clinical trials. **Tier 2 (Strong Preclinical + Mechanistic):** • Cardiac repair: Extensively studied in multiple animal MI models. Mechanism well-characterized: epicardial progenitor cell activation, coronary vasculogenesis, and anti-inflammatory effects. Multiple research groups have independently replicated findings. • Neurological repair: Rodent stroke and TBI models show functional improvement. Promotes white matter remodeling and synaptic plasticity. • Anti-fibrotic: Reduces fibrosis in kidney, liver, lung, and cardiac models through TGF-β pathway modulation. **Tier 3 (Emerging / Theoretical):** • Full-length TB-4 vs TB-500 fragment: Whether the full molecule has clinically meaningful advantages over fragments is unresolved. Theoretical arguments exist for enhanced intracellular activity of the full molecule.